Medication-assisted moderation: naltrexone, semaglutide questions, and app coaching

Three very different things have started showing up in the same search: naltrexone, a decades-old prescription pill; semaglutide, the diabetes-and-weight-loss drug people keep saying quieted their interest in alcohol; and coaching apps that promise to help you cut back from your phone. If you are weighing them against each other, the first useful thing to know is that they are not three versions of the same tool — and no honest comparison can crown a winner. One has an FDA indication for alcohol, one is an open research question, and one is not a medicine at all. Which mix fits you depends on your drinking pattern, your health history, and the kind of support you will actually use, and that is a conversation to have with a clinician, not a ranking to pick from.

What a comparison can do is make the three genuinely distinguishable, so the right questions go to the right place.

The short version

• Naltrexone is a prescription medication whose FDA label lists it for treating alcohol dependence. It is thought to dial down the rewarding lift a drink gives, which is why it comes up for people who want to drink less, not only for people who have already stopped.
• Semaglutide is FDA-approved for type 2 diabetes and weight management — not for alcohol. Researchers are studying GLP-1 drugs for drinking, and early findings are genuinely interesting, but using one for alcohol today is off-label — prescribed outside its approved uses — and unsettled.
• App coaching is structure, not chemistry: tracking, prompts, sometimes a human coach. It can carry a plan through an ordinary week; it cannot evaluate medication safety or diagnose anything.
• None of the three handles the most urgent scenario. If your body has come to depend on daily drinking, stopping abruptly can be dangerous — a question for a clinician first, and for 911 if severe symptoms like seizures or confusion ever appear.

Naltrexone: the one built for this

Naltrexone is a small tablet, taken daily, with a monthly injectable version; its FDA label lists alcohol dependence as an indication. The way it is thought to work is fairly easy to picture. Part of the pleasure of a drink comes from alcohol nudging the brain's opioid receptors — the same reward circuitry behind a runner's high. As the American Academy of Family Physicians explains, naltrexone blocks those receptors, so a drink lands with less of its usual lift. You can still drink on it; drinking just tends to feel less worth continuing. That makes it a different animal from disulfiram, an older medication that causes a physically unpleasant reaction if you drink. Naltrexone doesn't punish drinking — it deflates it.

Two cautions define its edges. It cannot be mixed with opioids: the same label rules it out for anyone taking opioid painkillers or dependent on them, because it blocks those drugs too. And the label is blunt that naltrexone hasn't been shown to help on its own, outside a broader plan for changing the drinking — worth holding onto, because it makes the medication-versus-coaching framing a false choice. For context, a systematic review from the federal Agency for Healthcare Research and Quality of outpatient medications for alcohol use disorder places oral naltrexone among the better-supported options — a mainstream medication, not a fringe one. There is a fuller picture in naltrexone for alcohol.

Semaglutide: the one under study

Semaglutide — the drug inside Ozempic and Wegovy — mimics a gut hormone called GLP-1 that signals fullness, which is how it earned its approvals for type 2 diabetes and weight management. Along the way, some people taking it began reporting something they hadn't asked for: less interest in alcohol.

Researchers took those reports seriously. In a study highlighted by NIH in 2026, people who received a GLP-1 medication alongside behavioral therapy reduced their heavy drinking more than people who got therapy alone. That is an encouraging early signal, and the operative word is early. Semaglutide has no FDA indication for alcohol use. Prescribing it for that purpose is off-label, and researchers don't yet agree on who it might help, for how long, or at what cost — it is a serious medication in its own right, with its own side effects and medical requirements. If it is on your mind, the productive version of the question is not "can I get it for drinking?" but "given my health picture, what is known and not known here — and is this conversation relevant to me or premature?"

App coaching: the one that isn't a medicine

Coaching apps do a different job entirely. At their best they offer drink tracking that shows you your real pattern, prompts that interrupt an automatic pour, a plan you set on a calm day and can find again on a hard one, and sometimes a human coach who follows up. That is behavior-change scaffolding — and it is not a consolation prize. The same AAFP guidance that endorses medications for alcohol use disorder recommends pairing them with behavioral support rather than relying on a prescription alone. Seen that way, a good app isn't competing with naltrexone; it can be the layer the medication is supposed to sit on.

Its limits are just as real. An app cannot tell whether your level of drinking makes stopping abruptly risky, cannot weigh a medication against the rest of your health history, and cannot notice what a clinician would notice across a visit. And because these tools live on your phone, privacy is a fair screening question: what data does the app collect, who can see it, and what shows up in your notifications.

Side by side

	Naltrexone	Semaglutide	App coaching
What it is	Prescription tablet, with a monthly injectable version	Prescription GLP-1 medication, usually a weekly injection	Software — tracking and prompts, sometimes with a human coach
How it's thought to work	Blocks the opioid receptors that give drinking part of its reward	Mimics a fullness hormone; its effect on drinking is still being studied	Supports habit change between the hard moments
Status for alcohol	FDA-indicated for alcohol dependence	Approved for diabetes and weight management; alcohol use is off-label and under research	Not a medical treatment; a support layer
Main caution	Off-limits with opioid painkillers; meant to work as part of a plan, not alone	Evidence is early; carries its own risks and medical requirements	Cannot assess withdrawal risk or medication safety

These are answers to different questions

Because the three do different jobs, "which one?" is often the wrong shape for the decision. The more common real-world outcome is a combination: a medication question that gets a proper clinical review, plus a behavioral layer — an app, a counselor, a structured plan — that guideline writers recommend alongside any prescription. Semaglutide is the odd one out for now: less an option to select than a research story to watch, and a topic to raise with a clinician if your health picture already involves it.

The scale of the untreated middle deserves one plain statistic. In 2024, an estimated 27.9 million people ages 12 and older in the United States had past-year alcohol use disorder — about 9.7% of that age group — and roughly 2.1 million of them, about 7.6%, received any alcohol-related treatment. That gap says more about access and awareness than about the tools: for most people, the medication conversation simply never happens.

Questions worth bringing to a clinician

You leave a comparison like this with better questions, not a verdict. A few that earn their place:

• Given my goal — cutting back versus stopping entirely — which of the approved medications is worth discussing first?
• I take, or sometimes take, opioid painkillers. Does that put naltrexone off the table for now?
• I've read about GLP-1 drugs and alcohol. What is actually known, and does my health history make that conversation relevant?
• Some mornings after heavy drinking I get shaky or sweaty. Do I need a plan for stopping safely before we talk about anything longer-term? (If stopping has ever brought on confusion, hallucinations, or a seizure, that is not a question for an appointment — call 911 or go to an emergency room.)
• Whatever we start with, what does follow-up look like, and how will we know whether it's working?

If the naltrexone question is the one you would ask first and there is no one to ask, that is the specific gap Clero is built for: it connects you with a licensed clinician by telehealth who can review whether the medication fits your situation.

No winner, on purpose

Set side by side, the options sort themselves into roles rather than a ranking. Naltrexone is the established, alcohol-indicated medication. Semaglutide is a promising research question wearing a famous brand name. App coaching is the connective tissue that either works better with. Many people end up using more than one — and which combination fits is individual enough that the deciding belongs in a conversation with a clinician who knows your history, not in an article, and certainly not in a checkout flow.

This article is general education, not medical advice or a recommendation. If stopping drinking has ever left you shaking badly, confused, or hallucinating, treat that as an emergency and call 911. If you are having thoughts of harming yourself, call or text 988. For confidential treatment referrals, SAMHSA's National Helpline is 1-800-662-4357.

Coming soon

Want the private naltrexone update?

Join the launch list to hear first. Today, this is still educational content, not a prescription request or clinical intake.

Get the naltrexone updateNot a prescription request, not medical advice, and not available for treatment today.